Stockscreener 앱 받기
4.88
2.52%
0.12
전일 마감가:
$4.76
열려 있는:
$4.81
하루 거래량:
286.87K
Relative Volume:
0.61
시가총액:
$282.86M
수익:
-
순이익/손실:
$-44.80M
주가수익비율:
-5.4831
EPS:
-0.89
순현금흐름:
$-30.67M
1주 성능:
+14.29%
1개월 성능:
-11.75%
6개월 성능:
+23.86%
1년 성능:
+100.00%
1일 변동 폭
$4.66
$5.005
1주일 범위
$4.09
$5.12
52주 변동 폭
$2.43
$6.5476
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
명칭
Aldeyra Therapeutics Inc
전화
781-761-4904
주소
131 HARTWELL AVENUE, LEXINGTON, MA
ALDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ALDX | 4.874 | 282.86M | 0 | -44.80M | -30.67M | -0.89 |
| VRTX | 449.80 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 747.39 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 593.04 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.15 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.32 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-04-02 | 재개 | H.C. Wainwright | Buy |
| 2022-04-27 | 재개 | H.C. Wainwright | Buy |
| 2021-02-08 | 개시 | H.C. Wainwright | Buy |
| 2020-12-16 | 개시 | Berenberg | Buy |
| 2020-10-30 | 개시 | Jefferies | Buy |
| 2020-10-16 | 개시 | BTIG Research | Buy |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-05-12 | 개시 | Oppenheimer | Outperform |
| 2018-12-04 | 개시 | Citigroup | Buy |
| 2018-09-26 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 개시 | Janney | Buy |
| 2018-01-26 | 개시 | Seaport Global Securities | Buy |
| 2016-09-26 | 개시 | H.C. Wainwright | Buy |
| 2016-07-01 | 개시 | Stifel | Buy |
| 2015-07-01 | 개시 | Canaccord Genuity | Buy |
| 2015-03-25 | 개시 | Chardan Capital Markets | Buy |
| 2015-03-20 | 재확인 | H.C. Wainwright | Buy |
| 2014-11-18 | 개시 | H.C. Wainwright | Buy |
| 2014-06-19 | 개시 | Aegis Capital | Buy |
모두보기
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap - MSN
Top US Penny Stocks To Watch In November 2024 - Simply Wall St
Aldeyra announces FDA acceptance of resubmitted reproxalap application - MSN
Aldeyra Therapeutics (ALDX) Refiles NDA for Innovative Dry Eye D - GuruFocus.com
5,578 Shares in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Bought by US Bancorp DE - Defense World
BTIG sets shares target with buy rating on Aldeyra, cites FDA read - Investing.com
Aldeyra Therapeutics Shares Up, FDA to Review New Drug Application - MarketWatch
FDA reviews Aldeyra's dry eye disease drug candidate By Investing.com - Investing.com Canada
Aldeyra announces FDA acceptance of resubmitted reproxalap application (NASDAQ:ALDX) - Seeking Alpha
FDA reviews Aldeyra's dry eye disease drug candidate - Investing.com
Aldeyra's Dry Eye Drug Gets FDA Review, Expands $400M AbbVie Partnership Deal | ALDX Stock News - StockTitan
What is Leerink Partnrs' Forecast for ALDX FY2024 Earnings? - MarketBeat
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Update - MarketBeat
Research Analysts Issue Forecasts for ALDX FY2028 Earnings - MarketBeat
Aldeyra Therapeutics CEO to Present at Jefferies London Healthcare Conference | ALDX Stock News - StockTitan
Aldeyra Therapeutics Insiders Who Sold Avert US$58m Market Cap Dip - Simply Wall St
Aldeyra’s FDA Resubmission And AbbVie Option Revitalize Reproxalap’s Prospects (ALDX) - Seeking Alpha
Nephrotic Syndrome Drugs Market Analysis of the Competitive - openPR
Is BellRing Brands (BRBR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
(ALDX) Trading Advice - Stock Traders Daily
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting - StockTitan
International Assets Investment Management LLC Buys 229,487 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
Short Interest in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Increases By 13.3% - MarketBeat
(ALDX) Long Term Investment Analysis - Stock Traders Daily
Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, - openPR
Neuropathic Ocular Pain Pipeline Assessment 2024: Therapies, Clinical Trials, Therapies, and Key Companies Involved by DelveInsight | Ocular Therapeutix, Aldeyra Therapeutics, Aciex Therapeutics - Barchart
Allergic Conjunctivitis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO - The Globe and Mail
Allergic Conjunctivitis Pipeline 2024: Clinical Trials - openPR
Aldyera therapeutics director Nancy Miller-Rich buys $10,446 in stock - Investing.com
(ALDX) Investment Analysis - Stock Traders Daily
Dimensional Fund Advisors LP Sells 210,153 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
Nephrotic Syndrome Drugs Market Set for Rapid Expansion with - openPR
(ALDX) Proactive Strategies - Stock Traders Daily
American Century Companies Inc. Acquires 36,528 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - Defense World
Renaissance Technologies LLC Sells 224,390 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
Lexington biotech resubmits dry eye drug for FDA approval a year after rejection - The Business Journals
Aldeyra Resubmits New Drug Application for Reproxalap for Dry Eye Disease - MD Magazine
Aldeyra Therapeutics stock affirmed at Outperform on NDA submission By Investing.com - Investing.com Canada
Aldeyra resubmits dry eye treatment NDA to FDA By Investing.com - Investing.com Australia
Aldeyra Therapeutics Files Again for FDA OK of Dry-Eye Disease Treatment - MarketWatch
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease - StockTitan
Aldeyra Therapeutics extends loan agreement terms - Investing.com India
Aldeyra Therapeutics extends loan agreement terms By Investing.com - Investing.com UK
Aldeyra Therapeutics, Inc. Enters into the Fourth Amendment to Loan and Security Agreement - Marketscreener.com
Aldeyra shares hold Outperform rating on pipeline progress By Investing.com - Investing.com Canada
What was Aldeyra Therapeutics Inc (ALDX)’s performance in the last session? - US Post News
Aldeyra Therapeutics Inc (ALDX) rating upgrades by Oppenheimer - Knox Daily
Market Watch Highlights: Aldeyra Therapeutics Inc (ALDX) Ends on an Upturn Note at 5.50 - The Dwinnex
Aldeyra Therapeutics Inc (ALDX) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Perceptive Advisors LLC Buys 682,265 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) - MarketBeat
(ALDX) Trading Signals - Stock Traders Daily
Aldeyra Therapeutics Inc (ALDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):